Tianjin TEDA Biomedical Engineering Balance Sheet Health
Financial Health criteria checks 4/6
Tianjin TEDA Biomedical Engineering has a total shareholder equity of CN¥59.1M and total debt of CN¥98.7M, which brings its debt-to-equity ratio to 167.1%. Its total assets and total liabilities are CN¥310.1M and CN¥251.0M respectively.
Key information
167.1%
Debt to equity ratio
CN¥98.65m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥92.73m |
| Equity | CN¥59.05m |
| Total liabilities | CN¥251.00m |
| Total assets | CN¥310.05m |
Recent financial health updates
Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?
Sep 12
Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?
Apr 07Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Nov 01Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt
Apr 21Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?
Oct 26Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?
Apr 06Recent updates
Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected
Dec 02There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price Jump
Oct 17There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price Jump
Aug 16Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some Risk
May 07Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?
Sep 12Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% Hiding
Apr 17Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?
Apr 07Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Nov 01Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt
Apr 21Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?
Oct 26Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?
Apr 06Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Dec 22
Financial Position Analysis
Short Term Liabilities: 8189's short term assets (CN¥200.4M) do not cover its short term liabilities (CN¥224.2M).
Long Term Liabilities: 8189's short term assets (CN¥200.4M) exceed its long term liabilities (CN¥26.8M).
Debt to Equity History and Analysis
Debt Level: 8189's net debt to equity ratio (10%) is considered satisfactory.
Reducing Debt: 8189's debt to equity ratio has increased from 16.6% to 167.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8189 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 8189 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 10.5% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 13:31 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianjin TEDA Biomedical Engineering Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|